August 25 - 27 | Boston MA

www.adc-toxicity.com

REGISTER BY FRIDAY, JUNE 5TH TO SAVE UP TO $1000

WELCOME | EXPERT SPEAKERS | AGENDA | PARTNER WITH US | REGISTER YOUR PLACE

4th Annual

adc Toxicity Summit

Preventing, Predicting & Mitigating ADC Toxicities

Unravelling ADC Toxicity Mechanisms to Prevent, Predict & Mitigate Safety Risks to Accelerate Translation of Traditional & Novel ADCs Towards Clinical Success

Expert Speakers Include:

Zenta Tsuchihashi
Head Senior Director, Translational Safety, Clinical Safety & Pharmacovigilance
Daiichi Sankyo

Doo Young Jung
Chief Executive Officer
PinotBio

Rodrigo Ruiz Soto
Chief Medical Officer
LigaChem Biosciences

abbvie

Oluwadamilola Ogunyankine
Senior Medical Director
AbbVie

Jutta Deckert
Vice President R&D
Iksuda Therapeutics

Meabh O'Hare
Fellow of Neurology
Brigham & Women's Hospital

"Relevant topics, informative presentations and open thoughts sharing"

Daiichi Sankyo

+1 415 735 3289 | info@hansonwade.com

www.adc-toxicity.com | Antibody Drug Conjugates

hansonwade

Your Dedicated Technical Deep Dive into Toxicity to Unlock the Full Therapeutic Potential of ADCs

4th Annual adc Toxicity Summit
August 25 - 27, 2026
Boston, MA

As ADC pipelines continue to grow, recent safety setbacks at Daiichi Sankyo, GSK, and CytomX have reinforced a critical challenge across the field: **toxicity remains one of the biggest barriers to ADC clinical success and patient safety**. With regulators placing greater emphasis on tolerability, dose optimization, and predictive safety strategies, the need to better understand and mitigate ADC toxicities has never been more urgent.

The **4th ADC Toxicity Summit** returns as the industry's only dedicated forum focused exclusively on advancing safer ADCs from preclinical development to the clinic.

Bringing together **toxicologists, translational scientists, pharmacologists, clinicians, and safety leaders**, this summit provides a highly focused environment to explore the mechanisms driving ADC toxicities, improve translation from preclinical models to patients, and de-risk next-generation ADC modalities including dual payloads, bispecifics, and novel linker-payload systems.

Join **70+ experts** from **pharma, biotech, and academia** for three days of technical deep dives, interactive discussion, and high-value networking dedicated to improving ADC safety, reducing patient risk, and accelerating the development of more tolerable ADCs.

50%
New Companies

25%
New Speakers

10+
Hours In-Person Networking

25%
C-Level

56%
VP/Director-level

Key Benefits of Attending

Advance predictive toxicology strategies by integrating organoids, microphysiological systems, computational modeling, and translational biomarkers to improve preclinical-to-clinical translation with **Bionavigen**, **Pfizer**, **Dana-Farber Cancer Institute**, and **Daiichi Sankyo**

Unravel the mechanistic drivers of ADC toxicity, including off-target uptake, bystander effects, ILD, ocular, and neurologic toxicities, to inform safer ADC design and smarter patient management with **PinotBio**, **Johnson & Johnson**, **AbbVie**, and **Brigham & Women's Hospital**

Navigate the evolving regulatory landscape surrounding dose optimization, Project Optimus, and FDA New Approach Methodologies **(NAMs)** to build regulator-ready safety packages and reduce reliance on animal testing with **LigaChem Bio**, **Bionavigen**, and **Johnson & Johnson**

De-risk next-generation ADC modalities, including dual-payloads, bispecifics, novel linker-payload systems, and emerging payload classes, by establishing fit-for-purpose translational and safety assessment frameworks with **Iksuda Therapeutics**, **Theratechnologies**, **Pfizer**, and **Pacylex Pharmaceuticals**

Leverage clinical safety data, translational PK/PD insights, and multidisciplinary management strategies to optimize dosing, improve early toxicity detection, and enhance patient outcomes across ADC programs with **Dana-Farber Cancer Institute**, **AbbVie**, and **LigaChem Bio**

+1 415 735 3289 info@hansonwade.com
www.adc-toxicity.com Antibody Drug Conjugates
hansonwade

Your Expert Speakers

4th Annual adc Toxicity Summit
August 25 - 27, 2026
Boston, MA

Pharma

Ganesh Swaminathan
Principal Scientist
Pfizer

Kwasi Amofa
Postdoctoral Scholar
J&J Innovative Medicine

Oluwadamilola Ogunyankin
Senior Medical Director, Safety Early Oncology Development
AbbVie

Philip Moquist
Director, ADC Chemistry
Pfizer

Zenta Tsuchihashi
Head Senior Director, Translational Safety, Clinical Safety & Pharmacovigilance
Daiichi Sankyo

Kazuyoshi Kumagai
Senior Director
Daiichi Sankyo

Biotech

Christian Marsolais
Senior Vice President & Chief Medical Officer
Theratechnologies Inc.

Doo Young Jung
Chief Executive Officer
Pinot Bio, Inc.

Jutta Deckert
Vice President, Research & Development
Iksuda Therapeutics

Matthew Sender
Director & ADC Project Lead
AntibodyChem Biosciences

Michael Weickert
Chief Executive Officer
Pacylex Pharmaceuticals, Inc.

Rakesh Dixit
President & Chief Executive Officer
Bionavigen

Rodrigo Ruiz-Soto
Chief Medical Officer
LigaChem Biosciences

Academia

Elad Sharon
Director, Clinical, Translational & Immunotherapy Toxicity Program
Dana-Farber Cancer Institute

Jae Young You
Ophthalmologist
Harvard Medical School

Meabh O'Hare
Fellow of Neurology
Brigham and Women's Hospital

Raad Chowdhury
Medical Director of Onconephrology
Brigham and Women's Hospital

Workshop Day
Tuesday, August 25, 2026

4th Annual adc Toxicity Summit
August 25 - 27, 2026
Boston, MA

Check in & Light Breakfast — 8.00

Workshop A — 9.00 - 12.00

Building Robust Preclinical Strategies to Validate New *In Vitro* Systems & Design Smarter, More Predictive Non-Clinical Packages

While first-in-human trials remain the ultimate test, this workshop focuses on how to de-risk programs earlier. It tackles the critical industry challenge of poor translation by moving beyond standard animal models to validate new *in vitro* systems and design smarter, more predictive non-clinical packages. Attend this workshop to improve the probability of clinical success by:

- Evaluating the predictive value of organoids, microphysiological systems, and computational models against historical clinical data for known toxicities like ILD and ocular toxicity.
- Developing a framework for reverse translation, using clinical safety signals to refine and calibrate preclinical models for better future predictions.
- Navigating the FDA's **NAMs** initiative. Discussing practical strategies for implementing New Approach Methodologies and preparing robust data packages to support regulatory submissions with reduced reliance on animal studies.

Workshop Leaders

Rakesh Dixit
President & Chief Executive Officer
Bionavigen

Ganesh Swaminathan
Principal Scientist
Pfizer

Lunch — 12.00

Workshop B — 1.00 - 4.00

Leveraging AI, Computational Modeling & Pharmacogenomics to Predict ADC Toxicity & Design Safer Therapies

As ADC pipelines grow more complex, traditional toxicology approaches alone are no longer sufficient to anticipate the multifactorial drivers of toxicity. This workshop explores how artificial intelligence, computational toxicology, and pharmacogenomic insights can be integrated to predict toxicity risks earlier and guide the design of safer ADCs. By combining multi-omic datasets with predictive modeling, attendees will learn how to identify patient-specific risk factors, anticipate organ-specific toxicities, and refine candidate selection before clinical development. Attend this workshop to harness data-driven approaches for safer ADC development by:

- Applying AI to identify toxicity risk patterns, using machine learning trained on preclinical and clinical datasets to link payload, linker, and antibody properties with organ-specific toxicities.
- Building computational models to predict ADC toxicity and integrate PK, biodistribution, and payload-release data into PBPK and systems pharmacology models to forecast exposure and dose-limiting toxicities.
- Leveraging pharmacogenomics to uncover patient risk factors to identify genetic variants affecting Fc-receptors, immune pathways, and drug transporters that influence ADC clearance and toxicity susceptibility.

Workshop Leader

Elad Sharon
Director of Clinical, Translational & Immunotherapy Toxicity Program
Dana-Farber Cancer Institute

End of Pre-Conference Workshop Day — 4.00

Conference Day One
Wednesday, August 26, 2026

4th Annual adc Toxicity Summit
August 25 - 27, 2026
Boston, MA

7.30 **Check in & Light Breakfast**

Mauricio Garcia-Atance
Program Director
Hanson Wade

8.35 **Program Director's Opening Remarks**

8.40 **Chair's Opening Remarks**

8.45 **Ice Breaker**

Unravelling the Mechanisms of ADC Toxicity to Inform Smarter Design & Create Safer Design Strategies

Doo Young Jung
Founder & CEO
PinotBio

9.00 **Understanding the Source of Toxicity to Create a Strategic Framework for Distinguishing Payload vs. Target-Mediated Effects**

- Employing a matched-pair strategy using inert payloads and non-binding antibodies, to systematically isolate and quantify the contributions of payload and target engagement to overall observed toxicity, providing a clear mechanistic attribution for dose-limiting adverse events
- Utilizing tissue microarrays with quantitative immunohistochemistry for target expression, to map the biodistribution of target antigens in critical normal organs, creating a preclinical risk assessment tool for on-target toxicity before candidate selection
- Developing computational toxicology models that partition free payload and intact ADC concentrations, to predict which component is driving clinical adverse events, informing linker design strategies to minimize systemic payload release

Matthew Sender
Director & ADC Project Lead
AntibodyChem Biosciences

9.30 **Re-Examining Limited Bystander Payloads to Translate Payload Design Principles into Improved ADC Safety Profiles**

- Reassessing the industry bias toward highly bystander-active payloads by evaluating how limited bystander payloads may reduce off-target toxicities while maintaining clinical efficacy
- Exploring how payload physicochemical properties, membrane permeability, and tumor biology influence the balance between efficacy, payload diffusion, and systemic safety
- Comparing preclinical and emerging clinical observations to understand why certain limited bystander payloads may outperform expectations in patients despite less pronounced preclinical activity

10.00 **Speed Networking: How does it work?**

10.05 **Speed Networking**
This informal session offers the perfect opportunity to connect with industry front-runners and key opinion leaders specializing in pathology and toxicity within the ADC field. This is your chance to build meaningful connections to carry through the rest of the conference, while gaining exclusive, first-hand insights into the latest research and developments.

10.45 **Morning Break & Networking**

11.30 **Roundtable Discussion: Uncovering the Mechanisms of Non-Specific ADC Uptake into Healthy Tissues Beyond Macropinocytosis**

Join this interactive roundtable to explore how non-specific ADC uptake into healthy tissues contributes to dose-limiting toxicities and what the industry can do to predict better, characterize, and mitigate these mechanisms early in development. Join this discussion to examine how emerging mechanistic insights can be translated into safer ADC design strategies and improved therapeutic window by:

- Investigating non-specific ADC uptake pathways beyond macropinocytosis by leveraging CRISPR-Cas9 screening and healthy cell models to identify the receptors and endocytic mechanisms driving off-target toxicities
- Understanding how ADC physicochemical properties such as surface charge, hydrophobicity, linker stability, and DAR influence non-specific uptake into healthy tissues, and debating which design parameters offer the greatest opportunity for toxicity mitigation
- Translating mechanistic insights from fluorescent imaging, spatial biology, and clinically validated ADC safety data into predictive screening strategies that enable earlier candidate prioritization and improved therapeutic windows

Zenta Tsuchihashi
Head Senior Director, Translational Safety, Clinical Safety & Pharmacovigilance
Daiichi Sankyo

Doo Young Jung
Founder & CEO
PinotBio

Matthew Sender
Director & ADC Project Lead
AntibodyChem Biosciences

Improving Translation from Preclinical Models to Clinical Outcomes & Exploring the Potential of Advanced *In Vitro* Systems

12.00 **Validating Novel *In Vitro* Models & Building More Predictive Nonclinical Packages for Smarter ADC Preclinical Strategies**

- Traditional nonclinical models often fail to predict clinical outcomes for complex ADCs, creating a need for more advanced and biologically relevant preclinical approaches.
- Novel *in vitro* systems can improve decision-making in drug discovery by providing better insights into key factors such as target uptake, payload characteristics, and tissue toxicity
- Integrating these systems into a broader translational strategy, along with improved species selection, biomarker use, and mechanistic data, can produce more predictive nonclinical packages and enable faster, more confident go/no-go decisions

Rakesh Dixit
President & Chief Executive Officer
Bionavigen

12.30 **Lunch & Networking**

Improving Translation from Preclinical Models to Clinical Outcomes & Exploring the Potential of Advanced *In Vitro* Systems - Continued

1.30 **Integrating *In Vivo* Monkey ILD Models with Single-Cell RNA Sequencing & BALF Extracellular Vesicle Proteomics to Improve Translational Understanding of DXd-ADC Pulmonary Toxicity**

- Developing a reproducible non-clinical monkey ILD model using repeated dosing of DXd-based ADCs to characterize pulmonary toxicities and establish translational relevance to clinical interstitial lung disease findings
- Longitudinally profiling plasma, BALF, and BALF-derived extracellular vesicles using high-dimensional proteomics to identify early biomarker candidates associated with ADC-induced lung injury progression
- Integrating single-cell RNA sequencing with extracellular vesicle proteomic signatures to map alveolar epithelial, macrophage, monocyte, and fibroblast responses, enabling mechanistic insight into DXd-ADC–associated ILD and improving translation from preclinical models to clinical outcomes

Kazuyoshi Kumagai
Senior Director
Daiichi Sankyo

Kwasi Amofa
Scientist Translational DMPK Sciences
Johnson & Johnson

2.00 Re-examined the Bystander Effect to Understand How Payload Properties & Tumor Microenvironment Influence Off-Target Toxicity

- Engineering an ADC panel with varying payload hydrophobicity to quantify how lipophilic payloads passively diffuse across cell membranes, establishing a predictive relationship between logD and off-target toxicities
- Investigating the contribution of membrane transporters to the bystander effect, including how influx and efflux mechanisms regulate intracellular payload accumulation and intercellular transfer, to determine their impact on off-target toxicity and therapeutic selectivity
- Correlating *in vitro* bystander killing potential in 3D spheroid co-cultures with *in vivo* outcomes to establish a predictive screening assay, enabling optimization of payload properties for an improved therapeutic index

2.30 Panel Discussion: Navigating the FDA's New Approach Methodologies Initiative Towards Reduced Animal Testing

The FDA's landmark guidance to reduce and ultimately replace animal testing has sent shockwaves through the toxicology community. The central question asks how to build a compelling, regulator-friendly safety package without decades of historical precedent.

Join regulatory experts, translational scientists, and industry pioneers as they chart a practical path forward for implementing **NAMs** in ADC development by:

- Building confidence in *in vitro* models, evaluating how organoids, microphysiological systems, and iPSC-derived tissue panels can be benchmarked against historical clinical data for known ADC toxicities like ILD and ocular keratopathy to establish predictive thresholds that regulators will trust
- Constructing a weight-of-evidence framework, discussing how to integrate high-content imaging, computational modeling, and mechanistic biomarker data into a cohesive safety package that compensates for the absence of traditional animal toxicology endpoints
- Collaborating with regulators on validation, exploring how to engage the FDA early in the **NAMs** development process through pre-IND meetings and qualification programs, ensuring that novel testing strategies are aligned with agency expectations and positioned for successful adoption

Rakesh Dixit
President & Chief Executive Officer
Bionavigen

Kwasi Amofa
Scientist Translational DMPK Sciences
Johnson & Johnson

Kazuyoshi Kumagai
Senior Director
Daiichi Sankyo

3.00 Afternoon Break & Poster Session

Connect with peers in a relaxed atmosphere and continue building new and existing relationships while exploring the latest advancements in ADC Toxicity Research. To submit a poster, please contact info@hansonwade.com

Leveraging Clinical Data to Optimize Dosing & Manage Patient Safety

Rodrigo Ruiz Soto
Chief Medical Officer
Ligachem Bio

4.00 Predicting Regulatory Expectations on Dose Optimization is Shaping ADC Clinical Development for Strategic Planning

- Analyzing recent regulatory feedback to interpret how the FDA's Project Optimus guidance is being applied to dose selection and toxicity mitigation strategies, providing a clear roadmap for designing Phase I dose-finding studies
- Designing clinical dose-optimization strategies for antibody–drug conjugates that balance therapeutic exposure and tolerability, to proactively address regulatory expectations
- Applying lessons from Ligachem Bio's ADC pipeline to integrate translational toxicology, pharmacokinetics, and early safety signals into adaptive Phase I study designs

Conference Day One
Wednesday, August 26, 2026

Elad Sharon
Director of Clinical, Translational & Immunotherapy Toxicity Program
Dana-Farber Cancer Institute

4.30 **Developing a Detailed Biorepository for Clinical Research in ADC Toxicity: Using Immunotherapy Toxicity Examples**

- Applying large language models to capture and structure real-time toxicity events from clinical data sources, enabling more comprehensive and timely identification of ADC-related adverse events
- Developing a clinically annotated framework for systematic collection of patient samples across clinical trials and standard-of-care settings, supporting integrated analyses of ADC toxicity mechanisms
- Leveraging advanced analytical techniques to characterize toxicity profiles and compare them with analogous sporadic events, enabling deeper mechanistic insights and more informed strategies for toxicity prediction and management

5.00 **Chair's Closing Remarks**

5.05 **End of Conference Day One**

"Topics are up to date and relevant to my job responsibilities. Presenters report new and review topics that are informative. Good engagement between speakers and audiences. Good size meeting focused on ADC Toxicity"

Oxford BioTherapeutics

"I love hearing perspectives from industry peers regarding the shared challenges we are facing"

AbbVie

Conference Day Two
Thursday, August 27, 2026

4th Annual adc Toxicity Summit
August 25 - 27, 2026
Boston, MA

8.00 **Check in & Light Breakfast**

8.55 **Chair's Opening Remarks**

Leveraging Clinical Data to Optimize Dosing & Manage Patient Safety

9.00 **Leveraging Clinical Phenotyping to Optimize ADC Dosing & Mitigate Neurologic Toxicities for Improved Patient Safety**

Meabh O'Hare
Fellow of Neurology
Brigham and Women's Hospital

- Applying detailed clinical phenotyping and electrophysiologic assessment to distinguish between immune-mediated and direct payload-related neurologic toxicities, enabling more precise dose modification and management strategies
- Characterizing neuromuscular toxicity patterns across ADC-treated patients to identify early clinical signals and correlate toxicity phenotypes with dosing exposure, supporting safer therapeutic windows
- Developing a clinician-led framework to differentiate subtypes of peripheral neuropathy and neuromuscular junction disorders, informing mechanism-driven management approaches and guiding multidisciplinary decision-making for treatment continuation or discontinuation

9.30 **Understanding a Clinician's Toolkit for ILD Early Detection, Diagnosis, & Management Strategies to Improve Patient Outcomes**

Oluwadamilola Ogunyankin
Senior Medical Director
AbbVie

- Developing a clinical algorithm for the early detection of ILD using high-resolution CT imaging and pulmonary function tests, to differentiate between early, reversible pneumonitis and progressive fibrosis, enabling timely intervention to prevent Grade 3-5 events
- Correlating serum biomarkers with the onset and severity of ILD in real-world patient cohorts, to validate a non-invasive monitoring tool for early detection, allowing clinicians to intervene before the onset of debilitating symptoms
- Building a multidisciplinary approach involving oncologists, pulmonologists, and radiologists, to establish standardized guidelines for the management of ILD and the criteria for safe re-challenge, improving patient outcomes and preserving the therapeutic option

10.00 **Panel Discussion: Aligning Clinical Experience with Translational Insights to Improve ADC Safety**

The disconnect between observed clinical toxicities and preclinical predictions continues to challenge ADC development and patient management. Treatments that appear tolerable in early studies can lead to unexpected adverse events in patients, complicating dosing decisions and long-term care. Join clinicians, clinical pharmacologists, and translational experts as they explore how to integrate clinical data, PK/PD insights, and real-world evidence to better interpret safety signals and inform treatment strategies by:

- Interpreting clinical safety signals to inform treatment decisions, exploring how systematic analysis of patient-level data can support dose modifications, treatment interruptions, and proactive toxicity management in clinical practice
- Leveraging translational and pharmacokinetic insights to contextualize toxicity risk, examining how physiologically based pharmacokinetic modeling and cross-species data can help clinicians anticipate adverse events, understand variability in patient response, and apply trial learnings to real-world populations
- Applying exposure-response relationships to guide dosing in the clinic, discussing how evolving dose optimization strategies, including those aligned with Project Optimus, can move toward individualized dosing approaches that balance efficacy and safety for different patient subgroups

Rodrigo Ruiz Soto
Chief Medical Officer
Ligachem Bio

Elad Sharon
Director of Clinical, Translational & Immunotherapy Toxicity Program
Dana-Farber Cancer Institute

Oluwadamilola Ogunyankin
Senior Medical Director
AbbVie

Conference Day Two
Thursday, August 27, 2026

10.30 **Morning Break & Networking**

Mitigating the Safety Risks of Novel ADCs to Overcome the Specific Challenges of Dual Payloads, Bispecifics & Novel Payloads

Jutta Deckert
Vice President R&D
Iksuda Therapeutics

11.00 **Understanding Translation from Preclinical Models to Clinical Outcomes for Novel Linker-Payload ADC Platforms**

- Attenuating payload platform toxicities through novel linker design
- Case studies for translatability of glucuronide linker ADC design with different payload classes
- Challenges of ADC toxicity assessment for linker-payloads with novel mechanisms of action

Michael Weickert
Chief Executive Officer
Pacylex Pharmaceuticals

11.30 **Evaluating Clinically Validated NMT Inhibitors as ADC Payloads**

- Characterizing the mechanism of action of NMT inhibitors across tumor models, to understand their potential as highly potent ADC payloads
- Assessing the preliminary clinical safety and antitumor efficacy of Zelenirstat as an oral therapeutic, to establish its therapeutic window and translational potential for payload development
- Evaluating the initial performance of NMT inhibitors as ADC payloads, to determine their effects on targeted cytotoxicity, payload stability, and antitumor activity while minimizing off-target toxicities

Christian Marsolais
Senior Vice President & Chief Medical Officer
Theratechnologies

12.00 **Enhancing Targeted Payload Delivery via Novel Receptor-Mediated Internalization to Mitigate Toxicity in Next-Generation ADCs**

- Leveraging a novel receptor-driven internalization mechanism to enable rapid, tumor-specific payload delivery, reducing systemic exposure and off-target toxicity compared to traditional ADCs
- Utilizing PDC architecture to achieve differentiated pharmacokinetics and improved safety profiles, addressing challenges associated with dual payloads and complex ADC formats
- Activating multimodal mechanisms of action to enhance efficacy while enabling safer combination strategies

12.30 **Lunch & Networking**

Navigating the Future ADC Combination Strategies to Manage Multi-Organ Toxicities & Create Effective Combination Regimens

Jae You
Instructor in Ophthalmology
Harvard Medical School

1.30 **Addressing the Unmet Need in Ocular Toxicity Through Mechanisms, Predictive Models, & Emerging Prophylactic Strategies**

- Profiling the molecular mechanisms of ADC-induced keratopathy using a human corneal epithelial cell model, to differentiate between payload-driven apoptosis and antibody-mediated inflammation, identifying specific interventions to block each pathway
- Validating a rabbit model for ocular toxicity that correlates with clinical findings for a panel of marketed ADC, to establish a robust non-clinical platform for ranking ocular safety liabilities, enabling confident lead selection for programs with a high risk of ocular tox
- Presenting Phase I/II data on novel prophylactic strategies, such as topical IVIG or targeted corticosteroid regimens, to demonstrate how proactive management can significantly reduce the incidence and severity of ocular adverse events, improving the overall risk-benefit profile for patients

Conference Day Two
Thursday, August 27, 2026

Philip Moquist
Director in ADC Chemistry
Pfizer

2.00 **Auristatin S: Developing an Auristatin Payload with Improved Tolerability & Modified Bystander Activity**

- Rationally designing Auristatin S to improve the tolerability of auristatin payloads through the tuning of permeability and bystander activity
- Explaining how Auristatin S maintains key auristatin properties, including strong tubulin binding affinity and induction of immunogenic cell death
- Exploring Auristatin S improved preclinical therapeutic window

2.30 **Panel Discussion: De-Risking Innovation & Creating a Framework for Preclinical Safety Assessment of Novel ADC Modalities**

As the ADC field rapidly expands beyond the established topoisomerase-I paradigm into dual-payload constructs, bispecific formats, and entirely novel toxin classes, the safety assessment playbook must evolve. With no historical safety data to rely on and toxicity mechanisms that may be fundamentally different from traditional ADCs, developers face an urgent need to establish new frameworks for predicting and mitigating risk.

Join preclinical safety leaders from biotech and large pharma as they share strategies for de-risking the next generation of ADC innovation by:

- Designing fit-for-purpose toxicology packages for dual-payload ADCs, debating whether standard NHP studies are sufficient to detect additive or synergistic toxicities, and exploring how staggered-dosing studies and payload-selective biomarkers can deconvolute the contribution of each warhead to the overall safety profile
- Assessing the unique liabilities of bispecific and biparatopic formats, discussing how altered binding avidity, internalization kinetics, and tissue distribution create novel safety challenges that require bespoke *in vitro* and *in vivo* models to accurately predict clinical risk
- Prioritizing novel payload classes by mechanistic profiling, evaluating how a standardized preclinical safety screening cascade, encompassing human primary cell panels, tissue organoids, and computational modelling, can rapidly identify the most promising payloads with differentiated toxicity profiles before committing to costly IND-enabling studies

Jutta Deckert
Vice President R&D
Iksuda Therapeutics

Christian Marsolais
Senior Vice President & Chief Medical Officer
Theratechnologies

Philip Moquist
Director in ADC Chemistry
Pfizer

3.00 **Chair's Closing Remarks**

3.05 **End of Conference**

> "It was nice to talk to people from a diverse background and learn from different perspectives. I like how many time the conference gave on networking and informal discussion"
>
> **Metrum Institute**

Opportunities to Partner

4th Annual adc Toxicity Summit
August 25 - 27, 2026
Boston, MA

Your Dedicated Platform to Showcase Toxicology, Translational & Safety Solutions to ADC Decision-Makers Actively Seeking Better Ways to Predict, Prevent & Mitigate Toxicity

As ADC pipelines continue to expand and evolve into dual-payload constructs, bispecifics, and novel linker-payload systems, toxicity remains one of the greatest barriers to successful clinical translation. Recent safety setbacks across the industry have intensified regulatory scrutiny and increased demand for more predictive preclinical models, translational strategies, biomarker approaches, and patient safety solutions. Yet many ADC developers lack the internal capabilities, technologies, and specialist expertise required to confidently predict, monitor, and mitigate toxicity risks across development.

Today's ADC leaders are actively seeking partners who can help **bridge the gap between preclinical findings and clinical outcomes**. They need collaborators who understand the complexities of ADC toxicology, translational science, dose optimization, and regulatory expectations, while delivering innovative solutions that improve patient safety and accelerate clinical success.

The **4th ADC Toxicity Summit** is the only dedicated industry forum exclusively focused on preventing, predicting, and mitigating ADC toxicities across preclinical and clinical development. This is your opportunity to showcase your expertise directly to the toxicologists, pharmacologists, translational scientists, clinicians, and safety leaders shaping the future of safer ADC development.

Support the ADC Toxicity Community With:

Predictive In Vitro & In Vivo Models including organoids, microphysiological systems, humanized models, and translational platforms that improve toxicity prediction and reduce reliance on animal testing

Translational & Biomarker Solutions that connect preclinical findings with clinical outcomes through PK/PD modeling, computational toxicology, omics approaches, and safety biomarker strategies

Clinical Safety & Patient Monitoring Capabilities supporting dose optimization, ILD management, ocular toxicity mitigation, pharmacovigilance, and real-world toxicity assessment

Analytical, Computational & AI-Driven Approaches that enable earlier identification of toxicity risks, improve candidate selection, and strengthen regulatory confidence for next-generation ADCs

Seniority of Attendees

- C-Level 6%
- President / VP 14%
- Director / Head 42%
- Manager 18%
- Team Lead 6%
- Academic 2%
- Other 10%

Type of Companies Attending



*Stats taken from The 3rd ADC Toxicity Summit

Get Involved

Nicholas Ramovic
Senior Business Development Manager
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Ready to Register?

3 Easy Ways to Book

ww.adc-toxicity.com/register

Tel: +1 617 455 4188

Email: info@hansonwade.com

Connect with 70+ ADC toxicology, translational, preclinical, and clinical safety leaders to deep dive into ILD, ocular, neurologic, and off-target toxicities impacting ADC development and patient outcomes.

Discover practical strategies to improve translation from preclinical models to the clinic using organoids, computational toxicology, biomarker approaches, and advanced *in vitro* and *in vivo* systems.

Future-proof your ADC development strategy with insights into dose optimization, FDA NAMs initiatives, dual-payload safety assessment, and translational frameworks designed to reduce patient risk and accelerate clinical success.

Elevate Your Attendance & Present a Poster: Take the opportunity to put your research and work in the spotlight!

Biotech & Pharma	Register & Pay By Friday, June 5th	On the Door Price
Full Package: Conference + Workshop Day	$3,397 (Save $1000)	$4,397
Conference Only	$2,599 (Save $500)	$3,099
Academics	**Register & Pay By Friday, June 5th**	**On the Door Price**
Full Package: Conference + Workshop Day	$2,797 (Save $1000)	$3,797
Conference Only	$2,199 (Save $500)	$2,699
Sevice Providers	**Register & Pay By Friday, June 5th**	**On the Door Price**
Full Package: Conference + Workshop Day	$4,297 (Save $1000)	$5,297
Conference Only	$3,299 (Save $500)	$3,799

*To qualify for the drug developer rate your company must have a public drug pipeline and not provide fee-based services. Please visit the website for full pricing options or email info@hansonwade.com

**To qualify for academic and research rate you must be full time academic. Please visit the website for full pricing options or email info@hansonwade.com

Do you work for a Not-for-Profit organization? Email us at info@hansonwade.com to inquire about attending

Team Discounts***

- **10% discount – 2 Attendees**
- **15% discount – 3 Attendees**
- **20% discount – 4+ Attendees**

***Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com



Venue

Revere Hotel Boston Common
200 Stuart St, Boston, MA 02116
www.reverehotel.com

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade Conferences Limited is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Conferences Limited, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom